showed that the risk of severe infection, defined as any infection leading to hospitalization, was higher for new users of infliximab and adalimumab compared to etanercept, lower for ustekinumab, and without increased risk for IL-17 and 23 inhibitors vs etanercept [41]. The gene discussed is IL17A; the disease is infection.